Supplements, Placebo, or Rosuvastatin Study

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 203 participants.

Also called NCT04846231

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 203 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04846231
Other papers using this trial's data
  • Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers Journal of the American College of Cardiology, 2023-01-03 DOI, PubMed 36351465

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04846231. Randomized; triple masking; primary purpose treatment. Start 2021-04-23 (actual); primary completion 2022-07-19 (actual). Results posted on 2023-05-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Supplements, Placebo, or Rosuvastatin Study
Acronym
SPORT
Condition
Hypercholesterolemia
Intervention (Dietary supplement)
Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice
Intervention (Drug)
Rosuvastatin
Intervention (Other)
Placebo
Lead sponsor
The Cleveland Clinic (class: other)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct04846231
Content hash
d05244a7b341d1d4ba6a8c8249b6d22113c204ec47ac62850c2f361b40397f42